- Activity pressure is positive on the latest completed week.
- Latest weekly return ranks in the strongest part of its sector group.
ONT
LSE
Week ended 07 Aug 2026
Weekly Investor Report
Oxford Nanopore Technologies plc · Healthcare · Biotechnology
Latest close
124.9 GBP
10.1%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -1.3% below the Trend Line and sits at 22.7% of its 52-week range. The latest completed week returned 10.1%, after a 3.8% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 50/100.
Setup score
32
out of 100
Latest Close
124.9 GBP
7 Aug 2026
1W Return
10.1%
latest completed week
4W Return
3.8%
short-term follow-through
12W Return
3.7%
quarterly tape
Trend Breadth
21.2%
11 of 52 weeks active
Volume Ratio
1.1x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
10.1%
Latest completed week; four-week move 3.8%.
Indicator stack
12/49
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
50/100
15 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -1.3% below the Trend Line and sits at 22.7% of its 52-week range. The latest completed week returned 10.1%, after a 3.8% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.2712-week average 0.25
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure10/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.27Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 3.8% over four weeks, 3.7% over 12 weeks, and -37.4% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year11
Trend breadth21.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.10Latest activity-pressure read.
Pressure change-41.2%Four-week change in activity pressure.
Leadership-17.04Latest relative-leadership reading.
RS change18.6%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Dec 2025
Field coverage 73%
Model confidence 58%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength1/100Blend of value, momentum, and quality. Underlying universe rank 100; rank 1 is best.
Value11/100Relative valuation strength. Underlying universe rank 90; rank 1 is best.
Quality3/100Profitability and accounting quality. Underlying universe rank 98; rank 1 is best.
Momentum2/100Medium-term price momentum. Underlying universe rank 99; rank 1 is best.
Growth90/100Revenue and earnings growth. Underlying universe rank 11; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 5.4x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -10.8% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 58.6% Gross profit retained from each unit of revenue.
- Operating margin
- -69.4% Operating profit retained from revenue.
- Free-cash-flow margin
- -51.9% Free cash flow generated from revenue.
- Return on invested capital
- -36.0% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 22.2% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -0.6% Net share repurchases relative to market value.
- Shareholder yield
- -0.6% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.6x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 15 relevant articles.
0 positive · 15 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-44.4%Distance below the 52-week high.
13-week volatility7.1%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher11 of 2614 weeks finished lower.
Best week+16.7%Week of 17 Apr.
Worst week-12.0%Week of 13 Mar.
Latest week+10.1%Week of 7 Aug.
Shape of recent returns
Strong gains8
Modest gains3
Flat weeks1
Modest losses4
Sharp losses10
Recent vol7.1%13-week weekly-return volatility.
Base vol7.0%52-week weekly-return volatility.
Up/down split25/26Count of positive and negative weeks in the 52-week window.
Average skew5.3% / -6.4%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorGB Healthcare
4-week rank30 / 79
Group average0.0%
Trend breadth27.8%
Trend27.8%active weekly trend signals
MD44.3%positive activity pressure
RS22.8%positive relative leadership
Four-week leaders
IndustryGB Biotechnology
4-week rank7 / 29
Group average-4.7%
Trend breadth13.8%
Trend13.8%active weekly trend signals
MD31.0%positive activity pressure
RS17.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape27/100
Trend, activity pressure, participation, and risk combine to a 27/100 tape read.
Indicator analysis31/100Latest 12-week confirmation: trend 0/12, activity pressure 10/12, relative leadership 0/12.
Activity pressure 0.27; No reversal markers Factors3/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 91; Small Cap Core rank 82 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 15 relevant articles.
Oxford Nanopore Number of Employees 2026 | Employee Count & Headcount Data Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 124.9 GBP | 10.1% | 126.5 GBP | 143.6 GBP | 0.10 | -17.04 | 5.3M | Off |
| 31 Jul 2026 | 113.4 GBP | 5.2% | 126.6 GBP | 144.4 GBP | 0.05 | -25.55 | 4.3M | Off |
| 24 Jul 2026 | 107.8 GBP | -4.0% | 127.1 GBP | 145.4 GBP | 0.11 | -29.57 | 5.0M | Off |
| 17 Jul 2026 | 112.3 GBP | -6.7% | 127.7 GBP | 146.4 GBP | 0.26 | -26.31 | 12.2M | Off |
| 10 Jul 2026 | 120.3 GBP | -0.1% | 128.2 GBP | 147.1 GBP | 0.17 | -20.93 | 4.4M | Off |
| 3 Jul 2026 | 120.4 GBP | -3.0% | 128.3 GBP | 147.8 GBP | 0.07 | -22.75 | 584.9K | Off |
| 26 Jun 2026 | 124.1 GBP | 6.5% | 129.0 GBP | 148.3 GBP | 0.12 | -19.52 | 2.0M | Off |
| 19 Jun 2026 | 116.5 GBP | 1.5% | 129.2 GBP | 149.0 GBP | 0.20 | -23.58 | 3.7M | Off |
| 12 Jun 2026 | 114.8 GBP | -11.9% | 129.7 GBP | 149.7 GBP | 0.19 | -25.71 | 976.5K | Off |
| 5 Jun 2026 | 130.3 GBP | -9.0% | 130.6 GBP | 150.5 GBP | 0.12 | -15.12 | 2.0M | Off |
| 29 May 2026 | 143.2 GBP | 10.7% | 130.8 GBP | 151.4 GBP | -0.24 | -7.27 | 5.7M | Off |
| 22 May 2026 | 129.4 GBP | 7.5% | 130.8 GBP | 152.2 GBP | -0.63 | -16.74 | 6.4M | Off |
| 15 May 2026 | 120.4 GBP | 6.5% | 131.2 GBP | 152.9 GBP | -0.88 | -20.70 | 8.1M | Off |
| 8 May 2026 | 113.1 GBP | -4.1% | 132.1 GBP | 153.7 GBP | -0.78 | -26.09 | 5.5M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.